Advancing a High-Value
Therapeutic Pipeline.
Structured preclinical validation driving toward rapid Phase I/II clinical readouts and strategic biopharmaceutical partnership milestones.
Development Programs & Clinical Stages
Four targeted indications addressing acute, chronic, and emergency wound-healing deficits using tailored delivery modalities.
Venous Leg Ulcers (VLU)
Delivery Modality: Bio-resorbable Matrix Film
Slow-release bioactive membrane designed to work synergistically under multi-layer compression wraps for chronic venous insufficiency wounds.
Deep Partial-Thickness Burns & Trauma
Delivery Modality: Aerosolized Bioactive Spray / Gel
Rapid field deployment formulation for thermal burn debridement and military combat wound triage without requiring cold chain logistics.
Surgical Incision Dehiscence & High-Tension Closures
Delivery Modality: Injectable Sub-dermal Depot / Suture Coating
Sustained-release formulation to enhance tensile burst strength and prevent surgical breakdown in high-risk laparotomy and orthopedic incisions.
Capital Efficiency & Targeted Use of Funds
Structured to maximize clinical value inflection points through Phase Ib human readouts.
Phase Ib Clinical Trial
Execution of 60-patient DFU open-label safety and preliminary re-epithelialization trial.
GLP Tox & CMC Scale-Up
Porcine GLP safety validation and commercial-grade cGMP batch manufacturing.
Pipeline Indication Expansion
Preclinical validation across expanded chronic ulcer and thermal burn indications.
Regulatory & G&A
Legal, regulatory filings, and general operating costs through Phase Ib.
Partner With ZegeneX
Explore co-development collaborations, territory licensing rights, and institutional investment opportunities in our lead and pipeline assets.
Request Partnering Package & Data Room Access